H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 76 Citations 16,277 235 World Ranking 779 National Ranking 27
Medicine D-index 90 Citations 25,468 305 World Ranking 5903 National Ranking 173

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Immune system

Rik J. Scheper spends much of his time researching Immunology, Molecular biology, Pathology, P-glycoprotein and Multiple drug resistance. His research on Immunology often connects related areas such as Cancer research. His Molecular biology study integrates concerns from other disciplines, such as FANCF, CD40, FANCA, Transmembrane protein and Membrane glycoproteins.

His Pathology research includes themes of ABCC6 and Drug resistance. His studies deal with areas such as Daunorubicin, NeuN, Transport protein and Blood–brain barrier as well as P-glycoprotein. Rik J. Scheper combines subjects such as Cell culture, Internal medicine, Gene and Multidrug resistance-associated protein 2 with his study of Multiple drug resistance.

His most cited work include:

  • Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. (765 citations)
  • The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria (674 citations)
  • The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. (601 citations)

What are the main themes of his work throughout his whole career to date?

Rik J. Scheper mostly deals with Immunology, Cancer research, Molecular biology, Cell biology and T cell. His Cancer research research is multidisciplinary, incorporating elements of Cell culture, P-glycoprotein, Multiple drug resistance, Pathology and Immunotherapy. His work carried out in the field of P-glycoprotein brings together such families of science as Daunorubicin and Abcg2.

His Multiple drug resistance research incorporates elements of Efflux and Pharmacology. In his study, Immunohistochemistry is strongly linked to Monoclonal antibody, which falls under the umbrella field of Molecular biology. The various areas that Rik J. Scheper examines in his T cell study include T lymphocyte and Cytokine.

He most often published in these fields:

  • Immunology (47.10%)
  • Cancer research (18.71%)
  • Molecular biology (18.39%)

What were the highlights of his more recent work (between 2006-2021)?

  • Immunology (47.10%)
  • Cell biology (13.87%)
  • Cancer research (18.71%)

In recent papers he was focusing on the following fields of study:

Rik J. Scheper mainly investigates Immunology, Cell biology, Cancer research, Immunotherapy and T cell. His Cytotoxic T cell research extends to Immunology, which is thematically connected. His Cell biology research incorporates themes from Langerhans cell, Cell culture, Keratinocyte, Dermis and Human skin.

His research on Dermis also deals with topics like

  • Epidermis which intersects with area such as Molecular biology,
  • Basement membrane and Pathology most often made with reference to Wound healing. His research integrates issues of Proteasome inhibitor, Bortezomib, Renal cell carcinoma and CD40 in his study of Cancer research. His study looks at the relationship between Immunotherapy and fields such as Prostate cancer, as well as how they intersect with chemical problems.

Between 2006 and 2021, his most popular works were:

  • Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein (339 citations)
  • Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial (290 citations)
  • Low Levels of Circulating Invariant Natural Killer T Cells Predict Poor Clinical Outcome in Patients With Head and Neck Squamous Cell Carcinoma (154 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Immune system

The scientist’s investigation covers issues in Immunology, Cell biology, Dendritic cell, Immune system and Immunotherapy. His Immunology study incorporates themes from Cancer, Cancer research, In vitro, Dermis and Epidermis. His research investigates the connection between Cancer research and topics such as PSMB6 that intersect with problems in Proteasome inhibitor.

His work carried out in the field of Cell biology brings together such families of science as Cell culture, CCL21, Pathology, CXC chemokine receptors and Human skin. Rik J. Scheper has included themes like Oral administration, Placebo, Hepatitis and Sensitization in his Immune system study. His Molecular biology research focuses on Proteasome and how it relates to T cell and Cytokine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene.

Coen C. Paulusma;Piter J. Bosma;Guido J. R. Zaman;Conny T. M. Bakker.
Science (1996)

999 Citations

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria

Johan W. Jonker;Marije Buitelaar;Els Wagenaar;Martin A. van der Valk.
Proceedings of the National Academy of Sciences of the United States of America (2002)

907 Citations

The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.

G.J.R. Zaman;M.J. Flens;M.R. van Leusden;M. de Haas.
Proceedings of the National Academy of Sciences of the United States of America (1994)

859 Citations

The drug resistance-related protein LRP is the human major vault protein

George L. Scheffer;Peter L.J. Wijngaard;Marcel J. Flens;Miguel A. Izquierdo.
Nature Medicine (1995)

845 Citations

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

Giuseppe Giaccone;Cornelis J A Punt;Yoshitaka Ando;Rita Ruijter.
Clinical Cancer Research (2002)

699 Citations

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

Jan B Vermorken;Anke M E Claessen;Harm van Tinteren;Helen E Gall.
The Lancet (1999)

596 Citations

Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.

Jan Hendrik Hooijberg;Henk J. Broxterman;Marcel Kool;Yehuda G. Assaraf.
Cancer Research (1999)

574 Citations

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs

Jan Wijnholds;Carla A. A. M. Mol;Liesbeth van Deemter;Marcel de Haas.
Proceedings of the National Academy of Sciences of the United States of America (2000)

561 Citations

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

Thomas P. Miller;Thomas M. Grogan;William S. Dalton;Catherine M. Spier.
Journal of Clinical Oncology (1991)

484 Citations

Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.

Markos Leggas;Masashi Adachi;George L. Scheffer;Daxi Sun.
Molecular and Cellular Biology (2004)

480 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Rik J. Scheper

Yuichi Sugiyama

Yuichi Sugiyama

University of Tokyo

Publications: 106

Tanja D. de Gruijl

Tanja D. de Gruijl

Vrije Universiteit Amsterdam

Publications: 102

Susan P. C. Cole

Susan P. C. Cole

Queen's University

Publications: 85

Jos H. Beijnen

Jos H. Beijnen

Antoni van Leeuwenhoek Hospital

Publications: 75

Alfred H. Schinkel

Alfred H. Schinkel

Antoni van Leeuwenhoek Hospital

Publications: 72

Gerrit Jansen

Gerrit Jansen

VU University Medical Center

Publications: 71

Roger G. Deeley

Roger G. Deeley

Queen's University

Publications: 65

George L. Scheffer

George L. Scheffer

VU University Medical Center

Publications: 63

John D. Schuetz

John D. Schuetz

St. Jude Children's Research Hospital

Publications: 62

Piet Borst

Piet Borst

Antoni van Leeuwenhoek Hospital

Publications: 58

Jouni Uitto

Jouni Uitto

Thomas Jefferson University

Publications: 56

Hiroyuki Kusuhara

Hiroyuki Kusuhara

University of Tokyo

Publications: 53

Dietrich Keppler

Dietrich Keppler

German Cancer Research Center

Publications: 51

Yehuda G. Assaraf

Yehuda G. Assaraf

Technion – Israel Institute of Technology

Publications: 48

András Váradi

András Váradi

Hungarian Academy of Sciences

Publications: 48

William S. Dalton

William S. Dalton

University of South Florida

Publications: 44

Something went wrong. Please try again later.